Clinical Prospect of Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles in Kidney Disease: Challenges and the Way Forward
Pharmaceutics · 09.07.2023 · 15 (7) · 1911
DOI: 10.3390/pharmaceutics15071911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 09.07.2023. Verfasst von Maja Kosanović und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11 000 Belgrade, Serbia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Ministry of Science, Technological Development and Innovation of the Republic of Serbia.
Abstract (Originalsprache)
Kidney disease is a growing public health problem worldwide, including both acute and chronic forms. Existing therapies for kidney disease target various pathogenic mechanisms; however, these therapies only slow down the progression of the disease rather than offering a cure. One of the potential and emerging approaches for the treatment of kidney disease is mesenchymal stromal/stem cell (MSC) therapy, shown to have beneficial effects in preclinical studies. In addition, extracellular vesicles (EVs) released by MSCs became a potent cell-free therapy option in various preclinical models of kidney disease due to their regenerative, anti-inflammatory, and immunomodulatory properties. However, there are scarce clinical data available regarding the use of MSC-EVs in kidney pathologies. This review article provides an outline of the renoprotective effects of MSC-EVs in different preclinical models of kidney disease. It offers a comprehensive analysis of possible mechanisms of action of MSC-EVs with an emphasis on kidney disease. Finally, on the journey toward the implementation of MSC-EVs into clinical practice, we highlight the need to establish standardized methods for the characterization of an EV-based product and investigate the adequate dosing, safety, and efficacy of MSC-EVs application, as well as the development of suitable potency assays.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for the Application of Nuclear Energy (INEP), University of Belgrade, 11 000 Belgrade, Serbia.
- Department of Neurosurgery, MD Anderson Cancer Center, University of Texas, Houston, TX 770302, USA.
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, 45355 Essen, North Rhine-Westhpalia, Germany.
- Vascular and Renal Translational Research Group, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), 25196 Lleida, Spain.
ORCID-Profile: Maja Kosanović, Tanja J Kutzner, Yanis Mouloud, Milica Bozic
Förderung
- Instituto de Salud Carlos III
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia
Zitieren
APA
Kosanović, M., Milutinović, B., Kutzner, T. J., Mouloud, Y., & Bozic, M. (2023). Clinical Prospect of Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles in Kidney Disease: Challenges and the Way Forward. Pharmaceutics, 15(7), 1911. https://doi.org/10.3390/pharmaceutics15071911
Vancouver
Kosanović M, Milutinović B, Kutzner TJ, Mouloud Y, Bozic M. Clinical Prospect of Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles in Kidney Disease: Challenges and the Way Forward. Pharmaceutics. 2023;15(7):1911. doi:10.3390/pharmaceutics15071911
BibTeX
@article{Kosanovi2023,
author = {Kosanović, Maja and Milutinović, Bojana and Kutzner, Tanja J and Mouloud, Yanis and Bozic, Milica},
title = {Clinical Prospect of Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles in Kidney Disease: Challenges and the Way Forward},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {7},
pages = {1911},
doi = {10.3390/pharmaceutics15071911}
}
EUVIMED